Vestal Point Capital, LP Arcellx, Inc. Transaction History
Vestal Point Capital, LP
- $1.9 Trillion
- Q2 2025
A detailed history of Vestal Point Capital, LP transactions in Arcellx, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 2,750,000 shares of ACLX stock, worth $213 Million. This represents 9.53% of its overall portfolio holdings.
Number of Shares
2,750,000
Previous 2,387,720
15.17%
Holding current value
$213 Million
Previous $157 Billion
15.61%
% of portfolio
9.53%
Previous 11.19%
Shares
6 transactions
Others Institutions Holding ACLX
# of Institutions
219Shares Held
49.1MCall Options Held
245KPut Options Held
885K-
Paradigm Biocapital Advisors LP New York, NY4.65MShares$360 Million14.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.94MShares$305 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$290 Million20.45% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$272 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$235 Million4.37% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.39B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...